According to the current guidelines, the use of osimertinib is a preferred treatment option for patients with completely resected stage IB–IIIA or IIIB (T3 and N2) NSCLC and positive for EGFR mutations (exon 19 deletion and exon 21 L858R) who have previously received adjuvant chemotherapy or are not eligible for platinum-based chemotherapy [69,70]. Here, EGFR is linked to non-small cell lung carcinoma.